Tumor necrosis factor-α (TNF-α)

Overview

tumor necrosis factor-α (TNF-α) is a small pro-inflammatory cytokine protein, the founding member of the TNF superfamily. It is synthesized as a type II transmembrane precursor that is cleaved by the metalloprotease TACE/ADAM17 to release a soluble form, which assembles into a homotrimer. TNF-α is produced chiefly by activated macrophages, but also by T-lymphocytes, natural killer cells, mast cells, and many non-immune cell types. It signals through two receptors, TNFR1 and TNFR2: TNFR1 engagement drives NF-κB and MAPK activation and, under some conditions, caspase-dependent apoptosis, while TNFR2 signaling is more restricted to immune and endothelial populations. Induction of TNF-α is a canonical downstream event of innate immune sensing — for example, lipopolysaccharide acting through Toll-like receptor 4 (TLR4) and NF-κB — and TNF-α in turn amplifies the same axis, coordinating expression of Interleukin-6 (IL-6), Interleukin-1β (IL-1β), C-X-C motif chemokine ligand 8 (CXCL8), C-C motif chemokine ligand 2, PTGS2/COX-2, and adhesion molecules that recruit leukocytes to inflamed tissue.

Because it sits at this hub, TNF-α is one of the most widely used readouts of inflammatory burden and one of the most heavily targeted proteins in medicine. Circulating TNF-α is measured alongside IL-6, interferon gamma (IFNG), and C-reactive protein (CRP) in immunoassays and newer multiplexed biosensing platforms, both in cytokine-storm states and in chronic conditions ranging from osteoarthritis and osteoporosis to polycystic ovary syndrome, metabolic and adipose tissue dysfunction, and intervertebral disc disease. Sustained TNF-α signaling contributes to cartilage degradation, bone resorption, insulin resistance, endothelial activation, and — via microglial activation in the central nervous system — the neuroinflammation implicated in Alzheimer's disease, often in concert with oxidative stress and reactive oxygen species. Therapeutically, TNF-α blockade with monoclonal antibodies and receptor-Fc fusion proteins is standard care in rheumatoid arthritis, inflammatory bowel disease, psoriasis, and ankylosing spondylitis, at the cost of increased susceptibility to infection, reflecting TNF-α's normal role in host defense. It also recurs as a top-ranked hub target in network pharmacology analyses of anti-inflammatory natural products such as quercetin, luteolin, and baicalein, typically appearing with IL-6 and PTGS2 in predicted protein–protein interaction cores.

Recent Publications Focus

• Recent work in a neuroinflammatory mouse model examined whether vorinostat could rescue cognitive deficits while modulating the hippocampal toll like receptor 4 (TLR4)/TRAF6/IKKα/NF-κB pathway and inflammatory mediators including TNF-α, IL-6, IL-1β, and iNOS, alongside neuroplasticity-related proteins such as BDNF and p-CREB. The study used western blot and qPCR to assess these markers and linked the treatment effect to suppression of neuroinflammation 42406171Jul.

• In a study of adipocyte thermogenesis and insulin sensitivity, luteolin-loaded WPI/Pueraria lobata amylopectin composite gel increased thermogenic gene expression in brown-differentiated C3H10T1/2 cells and reduced lipopolysaccharide-induced inflammatory cytokines, including Tnf-α, Il-6, and Il-1β, in RAW264.7 macrophages. This supports a dual metabolic and anti-inflammatory role for the formulation 42283235Jun.

• Polystyrene nanoplastics were reported to induce hippocampal damage and cognitive deficits through oxidative stress-triggered microglial extracellular traps and neuronal ferroptosis, with sustained neuroinflammation characterized by increased TNF-α and IL-1β. The findings connect TNF-α to microglia-driven inflammatory injury in the brain 42070744May.

• A veterinary clinical investigation in dogs with thoracolumbar intervertebral disc disease measured plasma inflammatory biomarkers including HIF-1α, TNF-α, IL-6, and total plasma NAD(H) levels during acupuncture treatment. The study placed TNF-α within a broader inflammatory and hypoxia-related biomarker panel 42371222Jun.

• In an Alzheimer’s disease-focused pharmacology study, lawsone was evaluated for multitarget anti-inflammatory effects, with expression of NF-κB, c-JNK, TNF-α, APP, Aβ1-42, and p-Tau assessed by qPCR and ELISA. The work positioned TNF-α as part of a proinflammatory signature linked to neurodegenerative pathology 42105996May.

• Spatial and temporal single-cell multi-omics in mice revealed that macrophages promote endometrial regeneration via TNF-α, and that TNF-α-induced SFRP4+ stromal cells enhance regeneration after transplantation. This study highlights TNF-α as a signaling mediator in tissue repair and stromal reprogramming 42234562Jun.

• Cryo-EM analysis of ozoralizumab, a humanized anti-TNFα NANOBODY compound, elucidated its interaction mechanism and supported its design as a potent inhibitor with a long plasma half-life. The publication directly addresses TNF-α neutralization as a therapeutic strategy 41935434Apr.

• In diabetic liver injury, TNF-α was described as a key pro-inflammatory cytokine promoting pyroptosis via the high mobility group box 1 (HMGB1)/toll like receptor 4 (TLR4)/MyD88/NF-κB pathway. This places TNF-α upstream of inflammatory amplification and cell death signaling 42219549May.

• A programmable metal-nucleic acid biomineralized hydrogel for infected wound healing used siTNF-α to silence TNF-α expression in macrophages, thereby reducing downstream pro-inflammatory cytokines including IL-6 and IL-1β. The study illustrates local TNF suppression as a strategy to improve wound repair 41941975Apr.

• In preterm fetal sheep, lipid emulsion did not alter inflammation-related genes such as Tnfa, Il-6, toll like receptor 4 (TLR4), and Tlr2 in skeletal muscle, suggesting no detectable effect on this inflammatory gene set under the conditions tested 41955312Apr.

• Hydatid cyst components were investigated for immunomodulatory and antitumor properties, with reported promotion of cytokines including IL-2, IFN-γ, TNF-α, and IL-4. TNF-α was therefore considered within a broader cytokine response associated with immune activation 41785598Mar.

• A dual-functional hydrogel designed for concurrent periodontitis and myocardial infarction treatment was reported to modulate the oral-cardiac inflammatory axis by downregulating B2 cell/TNF-α signaling, thereby mitigating systemic inflammation associated with MI. This study links TNF-α to both local periodontal inflammation and systemic cardiovascular injury 41810018Mar.

• A CRISPR/Cas-based HIV-1 study in latent CD4 T cell lines showed that proviral excision functionally blocked HIV-1 reactivation following stimulation with latency-reversing agents SAHA and TNFα. Here, TNFα served as a reactivation stimulus in a latency model 41769381Mar.

• Lemon balm-derived nanovesicles were tested in human skin fibroblasts exposed to a cytokine cocktail containing IL-22, IL-17A, and TNF-α to induce a pro-inflammatory state. The study focused on restoring mitochondrial function and reducing cytokine production under TNF-α-driven inflammatory conditions 41734866Feb.

• A thiadiazole derivative was identified through molecular docking as having notable affinity for the TNF binding site, with a reported binding energy of -8.69 kcal/mol. This suggests direct target engagement in silico, although the publication context provided here is limited to docking-based evaluation 41673348Feb.

• A systematic review and meta-analysis of bed rest and cardiometabolic health found that tumour necrosis factor alpha was elevated in both head-down bed rest and horizontal bed rest conditions. This supports TNF-α as a measurable systemic marker of inactivity-associated inflammation 41853886Mar.

• Another systematic review and meta-analysis focused on periodontitis reported significantly higher tumour necrosis factor α levels, alongside increases in IL-1β, IL-6, IL-17, IL-17A, IL-18, CCL2, Leptin (LEP), MMP-8, MPO, and RANKL. TNF-α thus appears as part of a consistent inflammatory biomarker profile in periodontitis 41910651Mar.

• Taohong Siwu Decoction was reported to switch detrimental and reparative astrocyte phenotypes after ischemic stroke by suppressing A1 markers including GFAP/C3, TNF-α, and iNOS while promoting A2 markers such as GFAP/S100A10, IL-10, and TGF-β. The study links TNF-α suppression to remyelination and oligodendrogenesis 41962609Apr.

• Chen’s Jinshui Pills were found to ameliorate diabetic retinopathy in mice, with network pharmacology and experimental validation indicating involvement of IL-6, TNF-α, and IL-17 pathways. The findings place TNF-α within an anti-inflammatory mechanism associated with intestinal barrier protection 41956232Apr.

• Network pharmacology-guided work on quercetin from cyathulae radix identified TNF among core targets in a protein-protein interaction network, alongside AKT1, IL-6, and MMP2. This supports TNF as a central node in the predicted anti-osteoporotic mechanism of the compound 42474720Jul.

• A study of Dolichos lablab flower extract predicted that multiple flavonoids, including quercetin, apigenin, kaempferol, luteolin, cirsimaritin, daidzein, genistein, and isorhamnetin, modulate inflammatory responses through core targets such as TNF, IL6, and PTGS2 and through pathways including TNF signaling. This reinforces TNF as a convergent target in multi-component anti-inflammatory pharmacology 42383440Jul.

• In a gut-ovarian axis study of Scutellaria baicalensis for polycystic ovary syndrome, molecular docking showed strong binding affinities between the main active components and the core targets TNF, AKT1, and IL-6. The work connects TNF to inflammatory regulation in a microbiota-associated endocrine disorder 42294648Jun.

What Changes, What Holds

1. Vorinostat appears to dampen TNF-α-linked neuroinflammation rather than alter the core pathway
REINFORCES Vorinostat is being used here as another example of suppressing the TLR4/TRAF6/IKKα/NF-κB axis and its downstream inflammatory mediators, including TNF-α. That fits the established view of TNF-α as a canonical output of innate immune activation and a marker of neuroinflammatory burden. The added neuroplasticity readouts broaden the phenotype, but they do not change TNF-α’s role in the inflammatory cascade 42406171Jul.

2. luteolin-based delivery retains the expected anti-inflammatory effect on TNF-α
REINFORCES The formulation’s reduction of Tnf-α, Il-6, and Il-1β in macrophages is consistent with the baseline account of TNF-α as a readout and mediator of inflammatory activation in metabolic and adipose contexts. The thermogenic findings add a metabolic angle, but the TNF-α result itself does not revise how the cytokine is understood; it supports the same anti-inflammatory direction already used in natural-product pharmacology 42283235Jun.

3. Nanoplastics add a brain-injury context for TNF-α without changing its inflammatory meaning
NEW DIRECTION This work places TNF-α in microglia-driven injury linked to oxidative stress, extracellular traps, and ferroptosis, a role not covered in the baseline. The established account already links TNF-α to neuroinflammation in Alzheimer’s disease, but not to this specific nanoplastic-induced mechanism. The evidence is preclinical and mechanistic, so it extends the map of TNF-α biology rather than overturning it 42070744May.

4. TNF-α remains a nonspecific inflammatory biomarker in veterinary disc disease
REINFORCES Measuring TNF-α alongside hypoxia-related markers in dogs with intervertebral disc disease does not alter the baseline understanding of the cytokine; it simply places it within another inflammatory biomarker panel. The result is useful for translational monitoring, but it does not establish a new mechanism or use. It reinforces TNF-α’s broad utility as a circulating readout of tissue inflammation 42371222Jun.

5. Lawsone keeps TNF-α in the proinflammatory signature of Alzheimer’s-related pathology
REINFORCES The study uses TNF-α as part of the same inflammatory network already described in the baseline for neuroinflammation and Alzheimer’s disease. Adding APP, Aβ1-42, and p-Tau does not change TNF-α’s role; it sharpens its placement within a multitarget disease signature. This is supportive pharmacology, not a challenge to the established account 42105996May.

6. TNF-α can also drive regeneration, not only inflammation
NEW DIRECTION Single-cell multi-omics assigns TNF-α a reparative role in endometrial regeneration and stromal reprogramming, which is not part of the baseline’s inflammatory-only framing. That does not contradict TNF-α’s pro-inflammatory biology, but it does show that the cytokine can participate in tissue repair programs under defined contexts. The finding is strong mechanistically, though still limited to a mouse regeneration model 42234562Jun.

7. Ozoralizumab strengthens the therapeutic case for direct TNF-α neutralization
REINFORCES Structural definition of an anti-TNFα nanobody compound supports, rather than revises, the established use of TNF-α blockade in inflammatory disease. The main value here is mechanistic clarity and drug-design support, not a new biological role for TNF-α. It reinforces the baseline view that TNF-α is a validated therapeutic target 41935434Apr.

8. TNF-α sits upstream of pyroptotic liver injury in diabetes
NEW DIRECTION This places TNF-α in a specific cell-death pathway for diabetic liver injury, which the baseline does not discuss. The established account already covers TNF-α-driven inflammation and metabolic dysfunction, but not HMGB1/TLR4/MyD88/NF-κB-linked pyroptosis in this organ. The result extends TNF-α biology into inflammatory cell death, though it remains preclinical 42219549May.

9. Local TNF-α silencing supports wound repair by lowering downstream inflammation
REINFORCES Using siTNF-α to reduce IL-6 and IL-1β in infected wound healing is a direct application of the baseline’s therapeutic logic: TNF-α sits upstream of inflammatory amplification and is a valid target for dampening tissue inflammation. The hydrogel delivery system is new, but the biological claim is not. It confirms that local TNF suppression can be used to improve repair 41941975Apr.

10. lipid emulsion did not measurably change Tnfa expression in fetal muscle
REINFORCES The negative result is consistent with the baseline’s caution that TNF-α is a context-dependent inflammatory marker, not a universally altered gene in every metabolic intervention. Because the study found no effect on Tnfa, Il-6, or Tlr genes, it does not revise TNF-α biology; it simply shows a lack of detectable response under these conditions 41955312Apr.

11. Hydatid cyst components broaden TNF-α’s place in immune activation
REINFORCES TNF-α is again being used as part of a general cytokine response, in line with the baseline’s description of it as a product of immune activation. The work does not introduce a new role or mechanism; it supports the idea that TNF-α rises with broader immune stimulation and may accompany antitumor or immunomodulatory effects 41785598Mar.

12. TNF-α signaling is implicated in the oral-cardiac inflammatory axis
NEW DIRECTION This study links TNF-α to a periodontal-to-cardiac inflammatory pathway, which the baseline does not cover. The established account already includes endothelial activation and systemic inflammation, but not this specific B2 cell/TNF-α axis connecting periodontitis and myocardial injury. The finding is hypothesis-generating and expands TNF-α’s disease network rather than replacing prior knowledge 41810018Mar.

13. TNFα remains a standard latency-reversing stimulus in HIV models
REINFORCES TNFα is being used exactly as expected here: as a stimulus that can reactivate latent HIV-1. That fits the baseline’s description of TNF-α as a potent inflammatory signal that amplifies transcriptional programs through NF-κB. The study’s main point is about proviral excision, not TNF biology, so it reinforces an established experimental use 41769381Mar.

14. TNF-α continues to define a proinflammatory skin-cell challenge state
REINFORCES The cytokine cocktail model uses TNF-α as part of a standard inflammatory induction system, which aligns with the baseline’s role for TNF-α as a driver of leukocyte-recruiting inflammatory programs. The mitochondrial rescue work is interesting, but it does not alter TNF-α’s meaning; it confirms its use as a proinflammatory stressor in cell culture 41734866Feb.

15. Docking data suggest a possible TNF-binding inhibitor, but not a biological revision
METHOD Molecular docking against the TNF binding site changes how the entity is studied, not what is known about it. The result is only in silico and does not establish a new role, pathway, or clinical use. It may help prioritize compounds for later testing, but it leaves the baseline account untouched 41673348Feb.

16. Bed rest elevates TNF-α, supporting its use as an inactivity-associated inflammatory marker
REINFORCES The meta-analysis strengthens the baseline view of TNF-α as a measurable systemic marker of inflammatory burden, now in the context of physical inactivity. It does not add a new mechanism, but it does show that TNF-α tracks with cardiometabolic stress during bed rest. That is confirmatory rather than transformative 41853886Mar.

17. Periodontitis consistently raises TNF-α as part of a broader inflammatory profile
REINFORCES The meta-analysis supports the established role of TNF-α as a circulating inflammatory biomarker. Periodontitis is another disease context in which TNF-α rises alongside other cytokines and tissue-remodeling markers, but the finding does not challenge the baseline. It simply sharpens the evidence that TNF-α is part of a reproducible inflammatory signature 41910651Mar.

18. TNF-α suppression may favor reparative astrocyte states after stroke
NEW DIRECTION This work places TNF-α in astrocyte phenotype switching and post-stroke repair, a role not described in the baseline. The established account emphasizes TNF-α as a pro-inflammatory mediator and neuroinflammatory driver, so showing that its suppression accompanies A2-like repair programs adds a new functional dimension. The evidence is preclinical and should be treated as context-specific 41962609Apr.

19. TNF-α remains a pathway node in diabetic retinopathy pharmacology
REINFORCES The study uses TNF-α as part of the same inflammatory pathway logic already present in the baseline, where TNF-α contributes to metabolic and vascular dysfunction. The intestinal barrier angle is novel for the disease model, but the cytokine’s role is not. This is another example of TNF-α-centered anti-inflammatory network pharmacology 41956232Apr.

20. quercetin network analysis again places TNF among core anti-osteoporotic targets
REINFORCES Identifying TNF as a core target alongside IL-6 and AKT1 is fully consistent with the baseline’s note that TNF-α repeatedly appears in network pharmacology cores for anti-inflammatory natural products. The paper adds another compound-specific example, not a new biological claim. It reinforces TNF’s status as a recurring hub in these analyses 42474720Jul.

21. Multiple flavonoids converge on TNF as a shared anti-inflammatory target
REINFORCES This broadens the same network-pharmacology pattern already described in the baseline: TNF is a central node repeatedly predicted for anti-inflammatory natural products. The value here is convergence across many compounds and pathways, but the underlying claim is familiar. It strengthens the idea that TNF is a common computational target, not a newly discovered one 42383440Jul.

22. TNF remains a core inflammatory target in PCOS-related docking studies
REINFORCES The docking results again fit the baseline’s description of TNF-α as a hub in metabolic and endocrine inflammation. PCOS is already mentioned in the overview as a condition associated with TNF-α, so this study mainly adds another mechanistic support layer. It does not alter the established account of TNF-α’s role 42294648Jun.

Overview update candidates: TNF-α can also participate in tissue repair and regeneration; TNF-α suppression may favor reparative astrocyte states after stroke; TNF-α is implicated upstream of pyroptotic diabetic liver injury; TNF-α is linked to microglia-driven nanoplastic brain injury.